Market: NMS |
Currency: USD
Address: 68 TW Alexander Drive
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
📈 Fennec Pharmaceuticals Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$15.21
-
Upside/Downside from Analyst Target:
98.55%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-03-10
-
EPS Estimate:
0.04
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Fennec Pharmaceuticals Inc.
| Date | Reported EPS |
|---|
| 2026-03-09 (estimated upcoming) | - |
| 2025-11-13 | -0.02 |
| 2025-08-14 | -0.11 |
| 2025-05-13 | -0.04 |
| 2025-03-10 | -0.06 |
| 2024-11-07 | -0.21 |
| 2024-08-13 | -0.2 |
| 2024-05-14 | 0.41 |
| 2024-03-21 | -0.1 |
| 2023-11-06 | -0.07 |
| 2023-08-03 | -0.21 |
| 2023-05-11 | -0.23 |
| 2023-03-29 | -0.26 |
| 2022-11-11 | -0.31 |
| 2022-08-12 | -0.19 |
| 2022-05-12 | -0.14 |
| 2022-02-28 | -0.17 |
| 2021-11-10 | -0.16 |
| 2021-08-10 | -0.15 |
| 2021-05-13 | -0.19 |
| 2021-03-30 | -0.13 |
| 2020-11-16 | -0.24 |
| 2020-08-05 | -0.21 |
| 2020-05-14 | -0.19 |
| 2020-02-14 | -0.18 |
📰 Related News & Research
No related articles found for "fennec pharmaceuticals".
